MX387467B - Forma física de un modulador sgr. - Google Patents

Forma física de un modulador sgr.

Info

Publication number
MX387467B
MX387467B MX2018011288A MX2018011288A MX387467B MX 387467 B MX387467 B MX 387467B MX 2018011288 A MX2018011288 A MX 2018011288A MX 2018011288 A MX2018011288 A MX 2018011288A MX 387467 B MX387467 B MX 387467B
Authority
MX
Mexico
Prior art keywords
sgr
modulator
physical form
methyl
phenylbutan
Prior art date
Application number
MX2018011288A
Other languages
English (en)
Other versions
MX2018011288A (es
Inventor
Deng Chaoyi
Original Assignee
Astrazeneca Ab
Astrazeneca Invest China Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Invest China Co Ltd filed Critical Astrazeneca Ab
Publication of MX2018011288A publication Critical patent/MX2018011288A/es
Publication of MX387467B publication Critical patent/MX387467B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Amplifiers (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Una forma cristalina de 2,2-difluoro-N-[(1R,2S)-3-metil-1-{[1-(1-metil-6-oxo-1,6-dihidropiridin-3-il)-1H-indazol-5-iI]oxi}-1-fenilbutan-2-il]propanamida (forma C), composiciones farmacéuticas que la contienen y su uso en terapia.
MX2018011288A 2016-03-23 2017-03-22 Forma física de un modulador sgr. MX387467B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2016/077095 WO2017161518A1 (en) 2016-03-23 2016-03-23 New physical form
PCT/EP2017/056838 WO2017162747A1 (en) 2016-03-23 2017-03-22 Physical form of a sgr modulator

Publications (2)

Publication Number Publication Date
MX2018011288A MX2018011288A (es) 2019-06-13
MX387467B true MX387467B (es) 2025-03-18

Family

ID=58398193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011288A MX387467B (es) 2016-03-23 2017-03-22 Forma física de un modulador sgr.

Country Status (13)

Country Link
US (1) US10407404B2 (es)
EP (1) EP3433248B1 (es)
JP (1) JP6651648B2 (es)
KR (1) KR102168931B1 (es)
CN (1) CN109415348B (es)
AU (1) AU2017238341A1 (es)
CA (1) CA3016507C (es)
CL (1) CL2018002577A1 (es)
ES (1) ES2926059T3 (es)
IL (1) IL261367A (es)
MX (1) MX387467B (es)
SG (1) SG11201807228QA (es)
WO (2) WO2017161518A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021136429A1 (zh) * 2019-12-31 2021-07-08 南京明德新药研发有限公司 苯并吡唑类化合物
EP4365171A4 (en) 2021-06-28 2025-07-09 Medshine Discovery Inc CRYSTALLINE FORM OF A TRIAZOLOPYRIDINE-SUBSTITUTED INDAZOLE COMPOUND AND PROCESS FOR ITS PREPARATION

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ564696A (en) * 2005-06-10 2011-05-27 Boehringer Ingelheim Int Glucocorticoid, indazole, mimetics, methods of making them, pharmaceutical compositions, and uses thereof
TW200815361A (en) 2005-10-20 2008-04-01 Astrazeneca Ab Chemical compounds
WO2007114763A1 (en) 2006-03-31 2007-10-11 Astrazeneca Ab Sulphonamide derivates as modulators of the glucocorticoid receptor
EP1878717A1 (en) 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
EP1917963A1 (en) 2006-10-31 2008-05-07 Bayer Schering Pharma Aktiengesellschaft Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents
EP1921067A1 (en) 2006-11-08 2008-05-14 Bayer Schering Pharma Aktiengesellschaft Indole and indazole derivatives as anti-inflammatory agents
WO2008055709A1 (en) 2006-11-08 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Indazole and indole derivatives as anti -inflammatory agents
TW200829578A (en) * 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) * 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
EP1958934A1 (en) 2007-02-16 2008-08-20 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents
EP2062880A1 (en) 2007-11-22 2009-05-27 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
EP2072509A1 (en) 2007-12-18 2009-06-24 Bayer Schering Pharma Aktiengesellschaft 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents
UY31832A (es) 2008-05-20 2010-01-05 Astrazeneca Ab Derivados de indazol sustituidos con fenilo y benzodioxinilo
EP2149558A1 (en) 2008-07-21 2010-02-03 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino-1-arylquinolin-2-ones, a process for their production and their use as anti-inflammatory agents
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
CA2839398A1 (en) 2011-06-29 2013-01-03 Bayer Intellectual Property Gmbh Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders
PE20171110A1 (es) * 2014-09-26 2017-08-07 Astrazeneca Ab Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos

Also Published As

Publication number Publication date
AU2017238341A1 (en) 2018-09-13
CN109415348A (zh) 2019-03-01
CN109415348B (zh) 2021-09-03
ES2926059T3 (es) 2022-10-21
WO2017161518A1 (en) 2017-09-28
EP3433248A1 (en) 2019-01-30
WO2017162747A1 (en) 2017-09-28
US20190106402A1 (en) 2019-04-11
EP3433248B1 (en) 2022-06-22
JP2019508474A (ja) 2019-03-28
SG11201807228QA (en) 2018-10-30
KR102168931B1 (ko) 2020-10-23
JP6651648B2 (ja) 2020-02-19
MX2018011288A (es) 2019-06-13
KR20180117178A (ko) 2018-10-26
IL261367A (en) 2018-10-31
CA3016507A1 (en) 2017-09-28
US10407404B2 (en) 2019-09-10
CL2018002577A1 (es) 2018-12-21
CA3016507C (en) 2020-10-13

Similar Documents

Publication Publication Date Title
ECSP20003147A (es) Carboxamidas como moduladores de los canales de sodio
CY1124097T1 (el) Κρυσταλλικο πολυμορφο της ελευθερης βασης της 2-υδροξυ-6-((2-(1-ισοπροπυλο-1η-πυραζολ-5-υλο)πυριδιν-3-υλο)μεθοξυ)βενζαλδεϋδης
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1122919T1 (el) Διεγερτες sgc
CY1123295T1 (el) Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
EA201892128A1 (ru) Гетероциклические амиды, полезные в качестве модуляторов
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
CL2017000240A1 (es) Compuestos activos hacia bromodominios
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
ZA201605979B (en) 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
SG10201808151RA (en) Cortistatin analogues and syntheses and uses thereof
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
MX2019011774A (es) N-(-1,3,4-oxadiazol-2-il)arilcarboxamidas sustituidas y su uso como herbicidas.
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου